Altogether, this data offers compelling evidence of the clinical prognostic value of the antagonistic relation of the pro-differentiation PRL/PRLR/Hippo/polarity protein complexes and further provide preclinical evidence of a therapeutic value of PRL, YAP inhibitor and their combination as a differentiation therapeutic target in breast cancer. Here, YAP1 is linked to breast carcinoma.